醇-氧化物纳米复合物通过抑制炎症,氧化应激和致病性来控制Toxoplasma gondii感染
Hanadi B A Baghdadi1,2, Aishah E Albalawi3, Abdullah F Shater4
1Biology Department, College of Science, Imam Abdurrahman Bin Faisal University, Dammam, Saudi Arabia.
Journal of basic microbiology
|May 1, 2024
概括
氧化物纳米颗粒 (Lin-ZNP) 通过减少寄生虫负载和炎症,有效地对抗Toxoplasma gondii感染. 这种新的纳米粒子治疗显示出显著的抗氧化活性,并抑制关键的炎症途径,而不会在小鼠中引起毒性.
科学领域:
- 纳米技术纳米技术
- 寄生虫学的寄生虫学
- 免疫学 免疫学 免疫学
背景情况:
- 托克索普拉斯马淋巴菌感染对全球健康构成重大挑战,需要新的治疗策略.
- 毒素菌现有的治疗方法可能有局限性和副作用.
- 基于纳米粒子的药物输送提供了一种有前途的方法,可以提高治疗效率并降低毒性.
研究的目的:
- 为了制造和表征氧化物纳米颗粒 (Lin-ZNP).
- 评估林-ZNP在体外和体内对毒素菌感染的疗效.
- 评估Lin-ZNP对炎症,氧化应激和寄生虫病原性的影响.
主要方法:
- 在乙醇溶液中使用聚乙烯醇合成的Lin-ZNP.
- 在体外评估抗毒素活性和细胞毒性.
- 在T. gondii感染的小鼠体内研究,涉及14天的Lin-ZNP治疗.
- 评估组织囊,抗氧化潜力,促炎性细胞因子和基因表达通过qPCR和西方 blot.
主要成果:
- 林-ZNP的平均尺寸为105nm,其塔基佐伊特活力显著降低,选择性指数高 (>10).
- 林-ZNP治疗显著降低了组织囊负担,甲水平,并通过TLRs/NF-κB通路下调炎症标志物.
- 治疗导致氧化 (NO) 生产增加,-3活性,抗氧化酶水平增加,并抑制了T. gondii病原性基因.
结论:
- 林-ZNP表现出强大的抗毒素活性与低细胞毒性.
- 林-ZNP的治疗作用归因于其抗氧化特性和抑制TLRs/NF-κB炎症途径.
- 林-ZNP代表了一种安全有效的治疗候选药物,用于治疗Toxoplasma gondii感染.
更多相关视频
06:42Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
Published on: September 27, 2024
1.6K
06:54Formulation of Zinc-Based Nanomaterials using the Eucommia ulmoides Bark Extract and their Wound Healing Potential
Published on: December 27, 2024
367
相关概念视频
Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
